Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2011

View Archived Issues

Novel PAK inhibitors reported by Afraxis

WARF scientists present novel vitamin D receptor ligands

Novel hepatocyte growth factor receptor inhibitors designed

SYL-1001 confers analgesia in animal model of ocular pain

Hutchison MediPharma presents preclinical data on new small-molecule anticancer agents

New MAb targeting anti-Muellerian hormone type-2 receptor suppresses ovarian tumors in vivo

BiTE antibody MT-112/BAY-2010112 targets prostate cancer

Glaucoma candidate ATS-907 shows promising efficacy and safety profile

Immunetics receives NIH grant for clinical trials of immunoblot test for Chagas' disease

Debiopharm and Yale University enter licensing agreement for Debio-1036

Akebia Therapeutics completes phase IIa pilot study of AKB-6548 for anemia

New inhibitors of lysine-specific histone demethylase 1A and/or MAO-B claimed

Aquaporin-9 expression demonstrated in malignant glioma biopsies

Novel estrogen receptor beta ligands prepared at Karo Bio

Northwest Biotherapeutics recruits additional patients in DCVax-Brain trial

Almirall and Nycomed enter co-branding agreement for roflumilast in Spain

Sanofi-aventis and Medicines for Malaria Venture enter alliance to develop malaria treatments

Allergan and Molecular Partners sign license agreement for MP-0112 in ophthalmic indications

Pharming and Santarus amend protocol for phase III Rhucin study

Mologen expands inclusion criteria for pivotal study of MGN-1703 in colorectal cancer

Savient Pharmaceuticals files MAA with the EMA for Krystexxa in chronic gout

PharmaGap provides update on liposomal delivery formulations of GAP-107B8

Enrollment in KAEL-GemVax's phase III pancreatic cancer vaccine trial exceeds 1,000 patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...